A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients
An analytical assay has been developed and validated for ultrafast and high-throughput mass spectrometric determination of pemetrexed concentrations in plasma using matrix assisted laser desorption/ionization-triple quadrupole-tandem mass spectrometry. Patient plasma samples spiked with the internal standard methotrexate were measured by multiple reaction monitoring. The detection limit was 0.4 fmol/μL, lower limit of quantification was 0.9 fmol/μL, and upper limit of quantification was 60 fmol/μL, respectively. Overall observed pemetrexed concentrations in patient samples ranged between 8.7 (1.4) and 142.7 (20.3)∈pmol/μL (SD). The newly developed mass spectrometric assay is applicable for (routine) therapeutic drug monitoring of pemetrexed concentrations in plasma from non-small cell lung cancer patients.
|Keywords||Alimta, MALDI-QqQ-MS/MS, Methotrexate, NSCLC, Pemetrexed, Therapeutic drug monitoring|
|Persistent URL||dx.doi.org/10.1007/s00216-010-4192-8, hdl.handle.net/1765/28616|
Meesters, R.J.W, Cornelissen, R, van Klaveren, R.J, de Jonge, R, den Boer, E, Lindemans, J, & Luider, T.M. (2010). A new ultrafast and high-throughput mass spectrometric approach for the therapeutic drug monitoring of the multi-targeted anti-folate pemetrexed in plasma from lung cancer patients. Analytical and Bioanalytical Chemistry, 398(7-8), 2943–2948. doi:10.1007/s00216-010-4192-8